

Q1 ReveraGen received a Bioethics supplement from the NIH to study a process of returning individual clinical trial data to patient families. We are returning data to study participants after the database is locked, the clinical study report written, and top-line results announced. One of the vamorolone clinical trial participants recently requested their data. We want to understand this issue from a physician perspective- thank you for completing this anonymous survey and answering the following questions.

much importance do you believe families place on receiving their son's individual clinical trial results?




ANSWER CHOICES	RESPONSES	
A great deal	50.00%	5
A lot	50.00%	5
A moderate amount	0.00%	0
A little	0.00%	0
None at all	0.00%	0
TOTAL		10

### Q2 How much importance do you believe families place on receiving their aggregate clinical trial results?




ANSWER CHOICES	RESPONSES	
A great deal	40.00%	4
A lot	40.00%	4
A moderate amount	20.00%	2
A little	0.00%	0
None at all	0.00%	0
TOTAL		10

## Q3 Do you think a parent/guardian should receive their child's individual clinical trial data if the parent requests it?



ANSWER CHOICES	RESPONSES	
Yes	100.00%	10
No	0.00%	0
TOTAL		10

## Q4 Do you agree with the concept of a Sponsor returning individual clinical trial data directly to trial participants?




ANSWER CHOICES	RESPONSES	
Yes	30.00%	3
No	10.00%	1
I'm not sure	10.00%	1
Yes, but it depends on the circumstances	50.00%	5
Total Respondents: 10		

# Q5 If you don't agree with the concept of a company returning clinical trial data to participants, can you list your concerns?

Answered: 8 Skipped: 2

#	RESPONSES	DATE
1	after trial is finished, data should be shared	6/21/2021 9:42 AM
2	What's meant by 'clinical trial data'? I don't think getting e.g. ECG, echo or MRI data is very useful and even some of the functional or strength measurements don't mean much to a family. It's a nice option for a family to see clinical trial data, but it would probably be more meaningful to provide them through a healthcare professional, either a doctor or a physiotherapist.	6/21/2021 3:55 AM
3	Has to go through PI, SI and/or site staff	6/21/2021 2:12 AM
4	Interpreting the data and put the individual data in the context of the study results and of a progressive disease might not be easy for all families and can create some false judgement and/or anxiety. It creates some "inequality" as proactive and well informed families are more likely to ask for the data	6/21/2021 1:48 AM
5	Not to disagree with this objective, but to raise the concern that the PI/treating physician for the participant could be blind-sided by the parent contacting the office and requesting an urgent discussion with the physician over an abnormal lab result. How to educate parents on labs/biomarkers/tests that are predicted to be abnormal (due to having DMD)? The poster does not go into this in any detail.	6/20/2021 7:46 PM
6	None	6/20/2021 7:28 PM
7	I agree, but it needs to be done in a thoughtful manner, properly contextualized.	6/4/2021 10:55 AM
8	at the end of the trial, all data should be returned to families. However, on a week by week basis during the trial, I don't favor providing results to individual families.	6/3/2021 2:49 PM

# Q6 Are you aware of additional questions/comments/concerns from parents/guardians directed to you/your team following return of their data from ReveraGen?



ANSWER CHOICES	RESPONSES	
Yes	20.00%	2
No	80.00%	8
TOTAL	1	10

# Q7 If your team received questions/concerns from parents/guardians about the returned data, can you elaborate on what types of questions/concerns they had?This question may be skipped if it does not apply.

Answered: 7 Skipped: 3

#	RESPONSES	DATE
1	Families have heard that data are supposed to be provided, but aren't certain how and when.	6/21/2021 3:55 AM
2	This is still hypothetical but the interpretation of the results, language barrier, cosequences for future therapies sjould be explained by the local physician	6/21/2021 2:53 AM
3	Does not apply.	6/21/2021 2:12 AM
4	It does not apply to a specific situation however it would be important that the clinician is also provided with exactly the same report to be able to answer the questions appropriately	6/21/2021 1:48 AM
5	as above - I anticipate parents will become alarmed over reviewing the labs/test results and where something unexpected comes to their attention. They often lack in context and are unable to sort out what is typical for DMD or a non-significant drug effect.	6/20/2021 7:46 PM
6	N/a	6/20/2021 7:28 PM
7	N/A	6/4/2021 12:07 AM

Q8 Do you have any feedback for ReveraGen on this process? This question may be skipped. Thank you for completing our survey!With best wishes from the ReveraGen team

Answered: 1 Skipped: 9